Drugs Made In America Acquisition Corp (DMAA)

Drugs Made In America Acquisition Corp Stock (DMAA) Forecast

The Drugs Made In America Acquisition Corp (DMAA) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $11.06, representing a +1.51% increase from the current price of $10.90. The highest analyst price target is $11.20, and the lowest is $10.93.

Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.

12-Month DMAA Price Target

Average 11.18 (+2.52% Upside)

Is Drugs Made In America Acquisition Corp (DMAA) A Buy Now?

Oscillators

Name	Value	Action
RSI(14)	68.38	Neutral
STOCH(9,6)	80.56	Sell
STOCHRSI(14)	100.00	Sell
MACD(12,26)	0.02	Sell
ADX(14)	15.00	Neutral
William %R	0.00	Sell
CCI(14)	111.62	Buy

Buy: 1 · Sell: 4 · Neutral: 2Summary: Sell

Moving Averages

Period	Simple	Exponential
MA10	10.88 Buy	10.89 Buy
MA20	10.88 Buy	10.88 Buy
MA50	10.84 Buy	10.83 Buy
MA100	10.75 Buy	10.76 Buy
MA200	10.61 Buy	10.63 Buy

Buy: 10 · Sell: 0 · Neutral: 0Summary: Buy

According to our latest analysis, DMAA could be considered a Strong Buy, with 17 technical analysis indicators signaling 11 Buy signals, 4 signaling Sell signals and 2 Neutral signals. This might be a good time to open fresh positions on DMAA, as trading bullish markets is always a lot easier

RSI (Relative Strength Index): The RSI(14) value of 68.38 indicates that DMAA is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
STOCH (Stochastic Oscillator): The STOCH value of 80.56 indicates that DMAA is overbought. This means that DMAA price is at or near the highest level over a specified lookback period.
STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 100.00 indicates that DMAA is overbought. This suggests that DMAA price is at or near the highest level relative to its recent price history.
ADX (Average Directional Index): The ADX value of 15.00 suggests that there may be some movement in price, but it lacks strength or conviction.
CCI (Commodity Channel Index): A CCI(14) value of 111.62 indicates that DMAA is overbought. This means that the price has moved significantly higher than its average, indicating a potential selling opportunity.

Long-term DMAA price forecast for 2026, 2030, 2035, 2040, 2045 and 2050

Based on our analysis about Drugs Made In America Acquisition Corp financial reports and earnings history, Drugs Made In America Acquisition Corp (DMAA) stock could reach $13.05 by 2030, $17.95 by 2040 and $23.10 by 2050. See the projected annual prices until 2050 of the Drugs Made In America Acquisition Corp stock below:

Drugs Made In America Acquisition Corp (DMAA) is expected to reach an average price of $15.57 in 2035, with a high prediction of $15.57 and a low estimate of $14.95. This indicates an +42.82% change from the last recorded price of $10.90.
Drugs Made In America Acquisition Corp (DMAA) stock is projected to chart a bullish course in 2040, with an average price target of $17.92, representing an +64.42% change from its current level. The forecast ranges from a conservative $17.32 to a sky-high $17.95.
Our analysts predict Drugs Made In America Acquisition Corp (DMAA) to change +91.94% by 2045, soaring from $19.95 to an average price of $20.92, potentially reaching $20.92. While $19.95 is the low estimate, the potential upside is significant.
Drugs Made In America Acquisition Corp (DMAA) stock is expected to climb by 2050, reaching an average of $23.08, a +111.75% change from its current level. However, a wide range of estimates exists, with high and low targets of $23.10 and $22.08, respectively, highlighting the market's uncertainty.

Drugs Made In America Acquisition Corp Stock (DMAA) Year by Year Forecast

Drugs Made In America Acquisition Corp Stock (DMAA) Price Forecast for 2026

The predicted value for Drugs Made In America Acquisition Corp (DMAA) in 2026 is set at an average of $10.69. Estimates vary from a peak of $11.20 to a trough of $10.37, indicating an -1.92% surge from the present price of $10.90.

Month	Average	Low	High	Change from today's price
December, 2026	$10.96	$10.93	$11.20	+0.51%

Drugs Made In America Acquisition Corp Stock (DMAA) Price Forecast for 2027

For 2027, Stockscan's Analyst expects the average price target for Drugs Made In America Acquisition Corp (DMAA) is $11.24, with a high forecast of $11.46 and a low forecast of $10.96. This indicates an +3.12% increase from the last price of $10.90.

Month	Average	Low	High	Change from today's price
January, 2027	$11.01	$10.96	$11.19	+1.00%
February, 2027	$11.06	$11.00	$11.08	+1.49%
March, 2027	$11.14	$11.07	$11.18	+2.17%
April, 2027	$11.21	$11.11	$11.22	+2.85%
May, 2027	$11.21	$11.17	$11.22	+2.89%
June, 2027	$11.23	$11.17	$11.25	+3.01%
July, 2027	$11.24	$11.21	$11.29	+3.13%
August, 2027	$11.28	$11.23	$11.30	+3.51%
September, 2027	$11.31	$11.28	$11.33	+3.77%
October, 2027	$11.34	$11.31	$11.34	+4.06%
November, 2027	$11.41	$11.33	$11.42	+4.65%
December, 2027	$11.44	$11.37	$11.46	+4.96%

Drugs Made In America Acquisition Corp Stock (DMAA) Price Forecast for 2028

In 2028, Drugs Made In America Acquisition Corp (DMAA) is projected to reach an average price of $11.73, with a high projection of $12.12 and a low estimate of $11.42. This indicates an +7.66% rise from the last price of $10.90.

Month	Average	Low	High	Change from today's price
January, 2028	$11.48	$11.42	$11.49	+5.36%
February, 2028	$11.51	$11.49	$11.55	+5.58%
March, 2028	$11.58	$11.51	$11.59	+6.25%
April, 2028	$11.61	$11.57	$11.61	+6.56%
May, 2028	$11.66	$11.61	$11.68	+6.96%
June, 2028	$11.70	$11.65	$11.71	+7.36%
July, 2028	$11.80	$11.69	$11.80	+8.22%
August, 2028	$11.89	$11.80	$11.89	+9.08%
September, 2028	$11.89	$11.82	$11.89	+9.11%
October, 2028	$11.87	$11.80	$11.89	+8.85%
November, 2028	$11.88	$11.86	$12.12	+9.01%
December, 2028	$11.94	$11.88	$12.12	+9.53%

Drugs Made In America Acquisition Corp Stock (DMAA) Price Forecast for 2029

The 2029 price forecast for Drugs Made In America Acquisition Corp Stock (DMAA) is $12.24 on average, with a high prediction of $12.47 and a low estimate of $11.93. This represents an +12.26% increase from the previous price of $10.90.

Month	Average	Low	High	Change from today's price
January, 2029	$12.03	$11.93	$12.04	+10.34%
February, 2029	$12.07	$12.03	$12.12	+10.77%
March, 2029	$12.15	$12.05	$12.16	+11.47%
April, 2029	$12.16	$12.12	$12.17	+11.55%
May, 2029	$12.18	$12.11	$12.20	+11.71%
June, 2029	$12.19	$12.16	$12.24	+11.86%
July, 2029	$12.24	$12.18	$12.26	+12.27%
August, 2029	$12.27	$12.23	$12.29	+12.57%
September, 2029	$12.30	$12.27	$12.30	+12.89%
October, 2029	$12.37	$12.30	$12.38	+13.52%
November, 2029	$12.41	$12.34	$12.43	+13.86%
December, 2029	$12.46	$12.39	$12.47	+14.30%

Drugs Made In America Acquisition Corp Stock (DMAA) Price Forecast for 2030

Drugs Made In America Acquisition Corp Stock (DMAA) is expected to reach an average price of $12.75 in 2030, with a high forecast of $13.05 and a low forecast of $12.46. This signifies an +16.93% surge from the last price of $10.90.

Month	Average	Low	High	Change from today's price
January, 2030	$12.49	$12.46	$12.53	+14.55%
February, 2030	$12.56	$12.49	$12.57	+15.25%
March, 2030	$12.60	$12.55	$12.60	+15.59%
April, 2030	$12.65	$12.59	$12.67	+16.03%
May, 2030	$12.69	$12.64	$12.70	+16.46%
June, 2030	$12.75	$12.69	$12.76	+16.98%
July, 2030	$12.89	$12.75	$12.89	+18.25%
August, 2030	$12.90	$12.82	$12.90	+18.32%
September, 2030	$12.79	$12.72	$12.90	+17.32%
October, 2030	$12.81	$12.78	$13.05	+17.50%
November, 2030	$12.87	$12.81	$13.05	+18.06%
December, 2030	$12.96	$12.86	$12.98	+18.91%